AIM: To assess medical and neurodevelopmental effects of Newborn Individualized Developmental Care and Assessment Program (NIDCAP) for a large sample of very early-born infants. METHODS:One hundred and seven singleton inborn preterm infants, <29 weeks gestational age (GA), <1250g birth weight, enrolled in three consecutive phases, were randomized within phase to NIDCAP (treatment, E) or standard care (C). Treatment extended from admission to the Newborn Intensive Care Unit to 2 weeks corrected age (wCA). Outcome included medical, neurobehavioural and neurophysiological status at 2 wCA, and growth and neurobehavioural status at 9 months (m) CA. RESULTS: The C- and E-group within each of the three consecutive phases and across the three phases were comparable in terms of all background measures; they therefore were treated as one sample. The results indicated for the E-group significant reduction in major medical morbidities of prematurity as well as significantly improved neurodevelopmental (behaviour and electrophysiology) functioning at 2 wCA; significantly better neurobehavioural functioning was also found at 9 mCA. CONCLUSION: The NIDCAP is an effective treatment for very early-born infants. It reduces health morbidities and enhances neurodevelopment, functional competence and life quality for preterm infants at 2 w and 9 mCA.
RCT Entities:
AIM: To assess medical and neurodevelopmental effects of Newborn Individualized Developmental Care and Assessment Program (NIDCAP) for a large sample of very early-born infants. METHODS: One hundred and seven singleton inborn preterm infants, <29 weeks gestational age (GA), <1250 g birth weight, enrolled in three consecutive phases, were randomized within phase to NIDCAP (treatment, E) or standard care (C). Treatment extended from admission to the Newborn Intensive Care Unit to 2 weeks corrected age (wCA). Outcome included medical, neurobehavioural and neurophysiological status at 2 wCA, and growth and neurobehavioural status at 9 months (m) CA. RESULTS: The C- and E-group within each of the three consecutive phases and across the three phases were comparable in terms of all background measures; they therefore were treated as one sample. The results indicated for the E-group significant reduction in major medical morbidities of prematurity as well as significantly improved neurodevelopmental (behaviour and electrophysiology) functioning at 2 wCA; significantly better neurobehavioural functioning was also found at 9 mCA. CONCLUSION: The NIDCAP is an effective treatment for very early-born infants. It reduces health morbidities and enhances neurodevelopment, functional competence and life quality for preterm infants at 2 w and 9 mCA.
Authors: José Villar; Mario Merialdi; A Metin Gülmezoglu; Edgardo Abalos; Guillermo Carroli; Regina Kulier; Mercedes de Onis Journal: J Nutr Date: 2003-05 Impact factor: 4.798
Authors: Heidelise Als; Frank H Duffy; Gloria B McAnulty; Michael J Rivkin; Sridhar Vajapeyam; Robert V Mulkern; Simon K Warfield; Petra S Huppi; Samantha C Butler; Nikk Conneman; Christine Fischer; Eric C Eichenwald Journal: Pediatrics Date: 2004-04 Impact factor: 7.124
Authors: Heidelise Als; Linda Gilkerson; Frank H Duffy; Gloria B McAnulty; Deborah M Buehler; Kathleen Vandenberg; Nancy Sweet; Elsa Sell; Richard B Parad; Steven A Ringer; Samantha C Butler; Johan G Blickman; Kenneth J Jones Journal: J Dev Behav Pediatr Date: 2003-12 Impact factor: 2.225
Authors: Celeste M Maguire; Frans J Walther; Paul H T van Zwieten; Saskia Le Cessie; Jan M Wit; Sylvia Veen Journal: Pediatrics Date: 2009-04 Impact factor: 7.124
Authors: Martha G Welch; Myron A Hofer; Susan A Brunelli; Raymond I Stark; Howard F Andrews; Judy Austin; Michael M Myers Journal: BMC Pediatr Date: 2012-02-07 Impact factor: 2.125
Authors: Gloria McAnulty; Frank H Duffy; Sandra Kosta; Neil I Weisenfeld; Simon K Warfield; Samantha C Butler; Moona Alidoost; Jane Holmes Bernstein; Richard Robertson; David Zurakowski; Heidelise Als Journal: BMC Pediatr Date: 2013-02-19 Impact factor: 2.125
Authors: Gareth Ball; James P Boardman; Tomoki Arichi; Nazakat Merchant; Daniel Rueckert; A David Edwards; Serena J Counsell Journal: PLoS One Date: 2013-07-03 Impact factor: 3.240